Pharmacological therapy for heart failure (HF) has evolved significantly in recent years. Conventional disease-modifying medical therapy HF with reduced ejection fraction (HFrEF), beta-blockers (BB), angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs), was complemented by two novel drug classes including angiotensin receptor neprilysin inhibitors (ARNIs) and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) which further improve outcomes in patients with HFrEF considerably. Major heart failure clinical practice guidelines advocate for the early initiation and uptitration of ‘quadruple’ medical therapy in HFrEF.1 2 However, implementation gaps still exist.3 There is an unmet need for evidence-based implementation strategies to achieve optimal guideline-directed medical treatment (GDMT). Treatment approaches in subgroups of patients with HF under-represented in clinical trials remain of significant clinical importance. The identification of the barriers to GDMT implementation in the real world is required. The scope of the Topic Collection was to gather emerging data on best practices of GDMT implementation in the real world, embracing the diversity of HF and psychosocial health patients with HF and capturing the broad spectrum of endpoints and …

中文翻译：

---

心力衰竭管理的新时代：有效实施尖端疗法

近年来，心力衰竭（HF）的药物治疗取得了显着进展。传统的改善病情的心力衰竭药物治疗包括降低射血分数 (HFrEF)、β-受体阻滞剂 (BB)、血管紧张素转换酶抑制剂 (ACEIs) 或血管紧张素受体阻滞剂 (ARB) 以及盐皮质激素受体拮抗剂 (MRA)，并辅以两种药物新型药物类别包括血管紧张素受体脑啡肽酶抑制剂 (ARNI) 和钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT-2is)，可进一步显着改善 HFrEF 患者的预后。主要心力衰竭临床实践指南提倡在 HFrEF 中尽早开始并逐步增加“四联”药物治疗。1 2 然而，实施差距仍然存在。3 对于以证据为基础的实施策略，以实现最佳指南指导的医疗治疗的需求尚未得到满足。治疗（GDMT）。临床试验中代表性不足的心力衰竭患者亚组的治疗方法仍然具有重要的临床意义。需要识别现实世界中 GDMT 实施的障碍。主题收集的范围是收集有关现实世界中 GDMT 实施最佳实践的新兴数据，涵盖心力衰竭和心力衰竭心理社会健康患者的多样性，并捕获广泛的终点和……